240 related articles for article (PubMed ID: 21987782)
1. Effects of somatostatin analogs on glucose homeostasis in rats.
Schmid HA; Brueggen J
J Endocrinol; 2012 Jan; 212(1):49-60. PubMed ID: 21987782
[TBL] [Abstract][Full Text] [Related]
2. Pasireotide (SOM230) prevents sulfonylurea-induced hypoglycemia in rats.
Schmid HA
Exp Clin Endocrinol Diabetes; 2015 Mar; 123(3):193-7. PubMed ID: 25658662
[TBL] [Abstract][Full Text] [Related]
3. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.
Schmid HA; Silva AP
J Endocrinol Invest; 2005; 28(11 Suppl International):28-35. PubMed ID: 16625842
[TBL] [Abstract][Full Text] [Related]
4. Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
Petersenn S; Unger N; Hu K; Weisshaar B; Zhang Y; Bouillaud E; Reséndiz KH; Wang Y; Mann K
J Clin Pharmacol; 2012 Jul; 52(7):1017-27. PubMed ID: 21673137
[TBL] [Abstract][Full Text] [Related]
5. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.
Henry RR; Ciaraldi TP; Armstrong D; Burke P; Ligueros-Saylan M; Mudaliar S
J Clin Endocrinol Metab; 2013 Aug; 98(8):3446-53. PubMed ID: 23733372
[TBL] [Abstract][Full Text] [Related]
6. SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?
Ruan W; Fahlbusch F; Clemmons DR; Monaco ME; Walden PD; Silva AP; Schmid HA; Kleinberg DL
Mol Endocrinol; 2006 Feb; 20(2):426-36. PubMed ID: 16223973
[TBL] [Abstract][Full Text] [Related]
7. Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary.
Nolan LA; Schmid HA; Levy A
Endocrinology; 2007 Jun; 148(6):2821-7. PubMed ID: 17347306
[TBL] [Abstract][Full Text] [Related]
8. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.
van der Hoek J; van der Lelij AJ; Feelders RA; de Herder WW; Uitterlinden P; Poon KW; Boerlin V; Lewis I; Krahnke T; Hofland LJ; Lamberts SW
Clin Endocrinol (Oxf); 2005 Aug; 63(2):176-84. PubMed ID: 16060911
[TBL] [Abstract][Full Text] [Related]
9. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
Breitschaft A; Hu K; Hermosillo Reséndiz K; Darstein C; Golor G
Diabetes Res Clin Pract; 2014 Mar; 103(3):458-65. PubMed ID: 24461109
[TBL] [Abstract][Full Text] [Related]
10. An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels.
Shenouda M; Maldonado M; Wang Y; Bouillaud E; Hudson M; Nesheiwat D; Hu K
Am J Ther; 2014; 21(3):164-73. PubMed ID: 22713526
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.
Hasskarl J; Kaufmann M; Schmid HA
Future Oncol; 2011 Jul; 7(7):895-913. PubMed ID: 21732759
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease.
Kugita M; Nishii K; Yamaguchi T; Suzuki A; Yuzawa Y; Horie S; Higashihara E; Nagao S
PLoS One; 2017; 12(5):e0177934. PubMed ID: 28542433
[TBL] [Abstract][Full Text] [Related]
14. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
Samson SL
Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
[TBL] [Abstract][Full Text] [Related]
15. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
Zatelli MC; Piccin D; Vignali C; Tagliati F; Ambrosio MR; Bondanelli M; Cimino V; Bianchi A; Schmid HA; Scanarini M; Pontecorvi A; De Marinis L; Maira G; degli Uberti EC
Endocr Relat Cancer; 2007 Mar; 14(1):91-102. PubMed ID: 17395978
[TBL] [Abstract][Full Text] [Related]
16. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
Bruns C; Lewis I; Briner U; Meno-Tetang G; Weckbecker G
Eur J Endocrinol; 2002 May; 146(5):707-16. PubMed ID: 11980628
[TBL] [Abstract][Full Text] [Related]
17. Route of administration as a factor in the selectivity of hormone suppression of a somatostatin analog in rats.
Lien EL; Garsky VM
Horm Metab Res; 1981 Dec; 13(12):675-8. PubMed ID: 6119282
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas.
Robben JH; Visser-Wisselaar HA; Rutteman GR; van Rijk PP; van Dongen AJ; Voorhout G; van den Ingh TS; Hofland LJ; Lamberts SW
J Nucl Med; 1997 Jul; 38(7):1036-42. PubMed ID: 9225787
[TBL] [Abstract][Full Text] [Related]
19. Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus.
Williams G; Füessl HS; Burrin JM; Chilvers E; Bloom SR
Horm Metab Res; 1988 Mar; 20(3):168-70. PubMed ID: 2898427
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-acting release octreotide on glucose homeostasis in acromegaly patients after trans-sphenoidal surgery.
Chen HS; Wu TE; Jap TS; Hsiao LC; Lin HD; Lee SH; Lin SH
Horm Metab Res; 2011 Jun; 43(6):433-9. PubMed ID: 21538290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
